Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran in Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy
Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran for the Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran for Hereditary Angioedema
Finlay Minerals Announces Closing of Non-Brokered Private Placement of Flow-Through and Non-Flow-Through Units
